SELLAS Life Sciences Group, Inc. $SLS Stock Sold by Everhart Financial Group Inc.

Everhart Financial Group Inc. reduced its position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 16.6% in the third quarter, Holdings Channel.com reports. The fund owned 240,213 shares of the company’s stock after selling 47,805 shares during the quarter. Everhart Financial Group Inc.’s holdings in SELLAS Life Sciences Group were worth $2,957,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SLS. Bank of New York Mellon Corp boosted its position in shares of SELLAS Life Sciences Group by 86.6% during the 1st quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock valued at $2,023,000 after acquiring an additional 221,957 shares during the last quarter. Bank of America Corp DE grew its stake in SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock worth $2,714,000 after buying an additional 540,748 shares in the last quarter. Dagco Inc. raised its position in shares of SELLAS Life Sciences Group by 19.8% during the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after buying an additional 203,653 shares in the last quarter. Wellington Management Group LLP grew its position in SELLAS Life Sciences Group by 73.2% in the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock worth $8,816,000 after acquiring an additional 252,531 shares in the last quarter. Finally, Quantinno Capital Management LP bought a new position in SELLAS Life Sciences Group in the first quarter valued at $315,000. Institutional investors own 17.38% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Price Performance

NASDAQ SLS traded down $0.16 during trading hours on Thursday, reaching $11.15. 2,429,929 shares of the company’s stock traded hands, compared to its average volume of 7,928,809. SELLAS Life Sciences Group, Inc. has a 52-week low of $1.39 and a 52-week high of $15.88. The firm has a 50-day simple moving average of $12.43 and a 200 day simple moving average of $9.61. The firm has a market cap of $2.25 billion, a PE ratio of -53.02 and a beta of 2.56.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company’s research and development programs are designed to address cancers with significant unmet medical needs.

SELLAS’s lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms’ tumor 1 (WT1), a protein expressed in several types of cancer.